759 results on '"Woude, C. Janneke"'
Search Results
2. Patients with immune mediated inflammatory diseases are insufficiently protected against vaccine-preventable infections
3. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
4. Evaluation of walking activity and gait to identify physical and mental fatigue in neurodegenerative and immune disorders: preliminary insights from the IDEA-FAST feasibility study
5. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease
6. Dutch normative data of the sexual distress scale and the body image scale
7. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
8. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
9. Endoscopic management of patients with high-risk colorectal colitis–associated neoplasia: a Delphi study
10. Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease
11. Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies
12. Faecal Microbiota Transplantation Engraftment After Budesonide or Placebo in Patients With Active Ulcerative Colitis Using Pre-selected Donors: A Randomized Pilot Study.
13. Systematic review: Patient‐related, microbial, surgical, and histopathological risk factors for endoscopic post‐operative recurrence in patients with Crohn's disease.
14. Addition of Platelet-Rich Plasma to Endorectal Advancement Flap Repair Does Not Enhance the Healing of Cryptoglandular Transsphincteric Fistulas.
15. Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study
16. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease
17. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study
18. Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn’s disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy
19. Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn’s Disease
20. Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis
21. Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn’s disease
22. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease
23. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
24. S6 Pregnancy Outcomes in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis: Results From the Ozanimod Clinical Development Program
25. A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process
26. Health-related quality of life in the first 5 years of the children born to mothers with IBD does not differ from children born to healthy mothers
27. Rotterdam Transition Test: A Valid Tool for Monitoring Disease Knowledge in Adolescents With Inflammatory Bowel Disease
28. Validation of the Pharmacokinetic Model for Anti-TNFα Clearance in Infants Exposed to Anti-TNFα During Pregnancy.
29. Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn's Disease.
30. Validation of the pharmacokinetic model for anti- TNFα clearance in infants exposed to anti- TNFα during pregnancy
31. Impact of timing of primary ileocecal resection on prognosis in patients with Crohn’s disease
32. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management
33. TNF-α exerts potent anti-rotavirus effects via the activation of classical NF-κB pathway
34. Cholecystectomy Risk in Crohn’s Disease Patients After Ileal Resection: a Long-term Nationwide Cohort Study
35. Fatigue in IBD: epidemiology, pathophysiology and management
36. Promoting equity in inflammatory bowel disease: a global approach to care
37. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.
38. Identification of Fatigue and Sleepiness in Immune and Neurodegenerative Disorders from Measures of Real-World Gait Variability
39. Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies
40. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
41. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study
42. Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies.
43. Autologous Platelet-Rich Stroma in Complex Perianal Fistulas
44. Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial
45. Isolated ileal blind loop inflammation after intestinal resection with ileocolonic anastomosis in Crohn’s disease: an often neglected endoscopic finding with an unfavorable outcome
46. Cardiovascular risk profiles in patients with inflammatory bowel disease differ from matched controls from the general population
47. Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry
48. 115 - ACONTECIMIENTOS ADVERSOS TROMBOEMBÓLICOS, CARDIOVASCULARES MAYORES ENTRE LOS PACIENTES INCLUIDOS EN EL PROGRAMA DE ENSAYOS CLÍNICOS DE FILGOTINIB
49. Cardiovascular risk profiles in patients with inflammatory bowel disease differ from matched controls from the general population
50. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission:The Randomized Controlled LADI Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.